Information Provided By: 
Fly News Breaks for July 31, 2015
MDVN
Jul 31, 2015 | 07:41 EDT
UBS said Medivation shares have been weak on concerns its Xtandi sales growth was decelerating. The firm said new Xtandi sales data has increased the firm's confidence and should ease concerns about demand growth for the drug. UBS reiterated its Buy rating and $142 price target on Medivation shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
